Sign in to enjoy up to 20% OFF or Register
  •  
[email protected]
Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
Multiplex IHC
Material Science
Others
+1 800-931-7508 [email protected]
Sign in to enjoy up to 20% OFF

[CAS NO. 88040-23-7]  Cefepime

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [88040-23-7]

Catalog
HY-B0692
Brand
MCE
CAS
88040-23-7

DESCRIPTION [88040-23-7]

Overview

MDL-
Molecular Weight480.56
Molecular FormulaC19H24N6O5S2
SMILESC[N+]1(CC(CS[C@]2([H])[C@@H]3NC(/C(C4=CSC(N)=N4)=N\OC)=O)=C(C([O-])=O)N2C3=O)CCCC1

For research use only. We do not sell to patients.

2 Publications Citing Use of MCE


Summary

Cefepime (BMY-28142) is a broad-spectrum and cross the blood-brain barrier cephalosporin. Cefepime shows antibacterial effects against both Gram-positive and Gram-negative aerobic bacteria. Cefepime induces neurotoxicity [1] [2] [3] [4] .


IC50 & Target

Gram-positive and Gram-negative aerobic bacteria [1]


In Vitro

Cefepime chloride exerts its antibacterial effects by binding to penicillin-binding proteins [2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

Cefepime (80 mg/kg; i.p.) significantly increases the half-life and mice surviveed [4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male CD-1 mice [4]
Dosage: 80 mg/kg
Administration: I.p.
Result: Significantly prolonged the half-life of cefepime and all mice survived at 18-22 mg/kg cisplatin, and when pretreatment with 26 mg/kg cisplatin significantly decreased survival with the half-life of cefepime was not significantly longer than of 18 mg/kg cisplatin.

Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT02680600 Onze Lieve Vrouw Hospital|University Ghent
Antimicrobial Treatment
March 2014 Not Applicable
NCT02820987 Centre Hospitalier Universitaire de Besancon
Septic Shock
September 1, 2016 Phase 3
NCT02497781 Pfizer|PRA Health Sciences
Complicated Urinary Tract Infections
September 24, 2015 Phase 2

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL ( 260.11 mM ; Need ultrasonic)

H 2 O : 83.33 mg/mL ( 173.40 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.0809 mL 10.4045 mL 20.8091 mL
5 mM 0.4162 mL 2.0809 mL 4.1618 mL
10 mM 0.2081 mL 1.0405 mL 2.0809 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.08 mg/mL (4.33 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (4.33 mM); Clear solution

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.33 mM); Clear solution

* All of the co-solvents are available by MCE.


Synonyms

Pyrrolidinium, 1-[[(6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-, inner salt
Pyrrolidinium, 1-[[7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-, inner salt, [6R-[6α,7β(Z)]]-
Pyrrolidinium, 1-[[(6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-, inner salt
BMY 28142
Cefepime
FR 81335
Tsefepim
Cefimen K
Sefdin

Information
Shipping
Privacy notice
Terms of Service
About us
Contact us
Customer services
Search
Custom Synthesis
My account
My account
Orders
Addresses
Shopping cart
Pay
Powered by Arctom Copyright © 2025 Arctom. All rights reserved.